Caption Management’s INmune Bio INMB Stock Holding History

Caption Management’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-689	Closed	-$4.37K	–	1293
2022 Q4	$4.37K	Buy	+689	New	+$4.89K	﹤0.01%	1223

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caption Management's INMB Position: Q1 2023 in Review

Caption Management sold out of INmune Bio (INMB) in Q1 2023, closing a stake of 689 shares — an estimated $4.37K sold.

Caption Management first reported a position in INMB in Q4 2022 and held it in 1 quarter. The position peaked at $4.37K in Q4 2022. 35 funds tracked by Wall St. Rank hold INMB as of Q1 2023.

Caption Management reported no remaining INmune Bio position as of Q1 2023 after selling out during the quarter.
Caption Management sold 689 INmune Bio shares in Q1 2023, an estimated $4.37K.
Caption Management first reported a position in INmune Bio in Q4 2022 and held it in 1 quarter.
Caption Management's INmune Bio position peaked at $4.37K in Q4 2022.
35 funds tracked by Wall St. Rank held INmune Bio as of Q1 2023.

Based on Caption Management's 13F filing for Q1 2023, filed 15 May 2023.